Paoluzzi L - Search Results

1

BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.

Paoluzzi L, Hanniford D, Sokolova E, Osman I, Darvishian F, Wang J, Bradner JE, Hernando E. Paoluzzi L, et al. Cancer Med. 2016 Jun;5(6):1183-93. doi: 10.1002/cam4.667. Epub 2016 May 11. Cancer Med. 2016. PMID: 27169980 Free PMC article.

2

Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.

Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, Zinzani PL, O'Connor OA. Marchi E, et al. Among authors: paoluzzi l. Clin Cancer Res. 2010 Jul 15;16(14):3648-58. doi: 10.1158/1078-0432.CCR-10-0671. Epub 2010 May 25. Clin Cancer Res. 2010. PMID: 20501616

3

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.

Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA. Paoluzzi L, et al. Clin Cancer Res. 2010 Jan 15;16(2):554-65. doi: 10.1158/1078-0432.CCR-09-1937. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068080

4

Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors.

Mieczkowska K, Jacob J, Paoluzzi L, Papalezova KT, McLellan BN, Amin B. Mieczkowska K, et al. Among authors: paoluzzi l. Melanoma Res. 2022 Apr 1;32(2):127-129. doi: 10.1097/CMR.0000000000000784. Melanoma Res. 2022. PMID: 35254335 No abstract available.

5

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA. Paoluzzi L, et al. Blood. 2008 Oct 1;112(7):2906-16. doi: 10.1182/blood-2007-12-130781. Epub 2008 Jun 30. Blood. 2008. PMID: 18591385 Free article.

6

Targeting survival pathways in lymphoma.

Paoluzzi L, O'Connor OA. Paoluzzi L, et al. Adv Exp Med Biol. 2010;687:79-96. Adv Exp Med Biol. 2010. PMID: 20919639 Review.

7

Histone deacetylase inhibitors are potent radiation protectants.

Paoluzzi L, Figg WD. Paoluzzi L, et al. Cancer Biol Ther. 2004 Jul;3(7):612-3. doi: 10.4161/cbt.3.7.931. Epub 2004 Jul 19. Cancer Biol Ther. 2004. PMID: 15136769 Free article. Review.

8

The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.

Bongero D, Paoluzzi L, Marchi E, Zullo KM, Neisa R, Mao Y, Escandon R, Wood K, O'Connor OA. Bongero D, et al. Among authors: paoluzzi l. Leuk Lymphoma. 2015;56(10):2945-52. doi: 10.3109/10428194.2015.1020058. Epub 2015 May 14. Leuk Lymphoma. 2015. PMID: 25860245

9

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.

Paoluzzi L, Gonen M, Gardner JR, Mastrella J, Yang D, Holmlund J, Sorensen M, Leopold L, Manova K, Marcucci G, Heaney ML, O'Connor OA. Paoluzzi L, et al. Blood. 2008 Jun 1;111(11):5350-8. doi: 10.1182/blood-2007-12-129833. Epub 2008 Feb 21. Blood. 2008. PMID: 18292288 Free article.

10

Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.

Paoluzzi L, O'Connor OA. Paoluzzi L, et al. BioDrugs. 2006;20(1):13-23. doi: 10.2165/00063030-200620010-00002. BioDrugs. 2006. PMID: 16573348 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters